Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Dec 2024 value amounting to $496,000.

  • Viridian Therapeutics, Inc.\DE's Gains from Investment Securities was N/A to $945,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $465,000, marking a year-over-year change of. This contributed to the annual value of $496,000 for FY2024, which is 1700.00% up from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Gains from Investment Securities is $496,000, which was up 1,700.00% from -$31,000 recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Gains from Investment Securities peaked at $496,000 during FY2024, and registered a low of -$77,000 during FY2021.
  • In the last 2 years, Viridian Therapeutics, Inc.\DE's Gains from Investment Securities had a median value of $232,500 in 2023 and averaged $232,500.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Gains from Investment Securities tumbled by 120.00% in 2021 and then soared by 1,700.00% in 2024.
  • Over the past 4 years, Viridian Therapeutics, Inc.\DE's Gains from Investment Securities (Yearly) stood at -$35,000 in 2020, then slumped by 120.00% to -$77,000 in 2021, then reached -$31,000 in 2023, then soared by 1,700.00% to $496,000 in 2024.